| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2015-01-08 | Atreus Pharmaceuticals (Canada) | Advanced Accelerator Applications (France) | undisclosed | Nuclear medicine |
| 2015-01-06 | OnCyte, the oncology division of Celdara Medical (USA - NH) | Cardio3 BioSciences, now Celyad (Belgium) | up to $ 161 million | Cancer - Oncology |
| 2015-01-06 | Optum Life Sciences services (USA - PA) | Mapi Group (France) | undisclosed | CRO Technology - Services |
| 2015-01-05 | Redvax (Switzerland) | Pfizer (USA - NY) | undisclosed | Vaccines Infectious diseases |
| 2014-12-22 | Topera (USA - CA) | Abbott (USA - IL) | $250 million upfront, plus potential future payments tied to performance milestones | Medical devices Cardiovascular diseases |
| 2014-12-18 | Kalon Biotherapeutics (USA - TX) | FUJIFILM Diosynth Biotechnologies U.S.A (USA - NC) | Technology - Services CMO |
|
| 2014-12-18 | OncoEthix (Switzerland) | Merck&Co (USA - NJ) | up to $ 365 million | Cancer - Oncology |
| 2014-12-18 | Dutalys (Austria) | Roche (Switzerland) | up to $ 488.75 million | Technology - Services |
| 2014-12-17 | EV-035 series of molecules from Evolva (Switzerland) | Emergent BioSolutions (USA - MD) | up to $ 70.5 million | Infectious diseases Bioterrorism |
| 2014-12-16 | Baxter\'s Vero cell technology and related assets, including its production facility (USA - IL) | Nanotherapeutics (USA - Fl) | undisclosed | Vaccines Infectious diseases |
| 2014-12-12 | Veropharm (Russia) | Abbott (USA - IL) | $305 million | |
| 2014-12-08 | Cubist Pharmaceuticals (USA - MA) | Merck&Co (USA - NJ) | $9.5 billion (€7.72 billion) | Infectious diseases Hospital care |
| 2014-12-04 | PneumRx (USA - CA) | BTG (UK) | up to $245 million | Lung diseases Respiratory diseases |
| 2014-12-02 | Ariosa Diagnostics (USA - CA) | Roche (Switzerland) | undisclosed | Diagnostic |
| 2014-12-02 | Zeltia (Spain) | PharmaMar(Spain) | Cancer - Oncology | |
| 2014-11-28 | Covidien (Ireland) | Medtronic (USA - MN) | $42.9 billion | Medical devices Medical technologies Health services |
| 2014-11-28 | Flamel Technologies \' manufacturing facility (France) | Recipharm (Sweden) | €10.6 million | |
| 2014-11-24 | Prosensa (The Netherlands) | Biomarin Pharmaceutical (USA - CA) | up to $840 million | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2014-11-17 | Allergan (USA - CA) | Actavis (Ireland) | $ 66 billion (€ 52.7 billion) | |
| 2014-11-13 | Lusomedicamenta (Portugal) | Recipharm (Sweden) | SEK 1.04 billion (€112.3 million) | Production Manufacturing |
